Aortic valve stenosis in 2026: from emerging mechanisms to clinical drug development

Atherosclerosis · Published 2026-08-01 · DOI 10.1016/j.atherosclerosis.2026.121865

Free full text

Authors (5)

Kang H. Zheng, Emilie L. Gaillard, Jeffrey Kroon, Erik S.G. Stroes, S. Matthijs Boekholdt

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zheng, K., Gaillard, E., Kroon, J., et al. (2026). Aortic valve stenosis in 2026: from emerging mechanisms to clinical drug development. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2026.121865

Related articles

• Persistent gaps in management and risk factor control among patients with atherosclerotic cardiovascular disease: All of us research program · Atherosclerosis · 2026 · Same journal
• Standard modifiable cardiovascular risk factors and acute coronary syndrome free survival · Atherosclerosis · 2026 · Same journal
• Lipid profile in pediatric and adult patients with lysosomal acid lipase deficiency treated with sebelipase alfa: longitudinal evidence from the International LAL-D Registry · Atherosclerosis · 2026 · Same journal
• CD146 extracellular vesicles accumulate at atherosclerotic lesions, reducing inflammation and atheroma burden · Atherosclerosis · 2026 · Same journal
• NOD1 ligand FK565 promotes atherogenesis and accumulation of NOD1+ smooth muscle cells in atherosclerotic lesions · Atherosclerosis · 2026 · Same journal
• Precision and network medicine in cardiovascular prevention and disease · Atherosclerosis · 2026 · Same journal
• Dietary vitamin K intakes and atherosclerotic cardiovascular disease incidence: Findings from the UK biobank · Atherosclerosis · 2026 · Same journal
• Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study · Atherosclerosis · 2026 · Same journal
• Culprit in custody but disease remains at large: OCT substrate and the residual SYNTAX score · Atherosclerosis · 2026 · Same journal
• Elevated remnant cholesterol, but not LDL cholesterol, explains part of recurrent ASCVD events in individuals with and without impaired renal function: the Copenhagen General Population Study and the UK Biobank · Atherosclerosis · 2026 · Same journal